Guidance

Background

Background

Gilead Sciences was invited to submit evidence for the single technology appraisal of idelalisib for treating follicular lymphoma that is refractory to 2 prior lines of treatment in July 2014.

The company informed NICE that it would not be making an evidence submission. It stated that the currently available data would not allow for a meaningful and robust submission of evidence for this appraisal and that relevant trials were ongoing. The company stated that it would inform NICE as any significant new evidence becomes available to enable a future submission.